Morgan Stanley Reiterates Equal-Weight on Pharvaris, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris (NASDAQ:PHVS) and maintained a $10 price target.
June 26, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris and maintained a $10 price target.
The news of Morgan Stanley reiterating an Equal-Weight rating on Pharvaris and maintaining a $10 price target is neutral for the stock price in the short term. The rating suggests that the stock is fairly valued and the price target is unchanged, indicating no significant change in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100